We work on drug discovery by combining our proprietary global top level antibody engineering and cyclic peptide technology and biological hypothesis of disease causing mechanism to solve the unmet medical needs.

Recycling Antibody®

Our proprietary Recycling Antibody® technology enables a single antibody molecule to bind to an antigen multiple times whereas conventional antibodies bind only once. This is achieved by engineering antibodies to dissociate from the antigen at acidic pH within the endosome. Recycling Antibody® technology was applied to create the FDA-approved product, ENSPRYNG® (satralizumab), and we have multiple antibodies currently being tested in clinical studies and throughout the drug discovery process.

Recycling Antibody® is a registered trademark of Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan)

Reference Article:

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

Nature Biotechnology volume 28, pages 1203–1207 (2010)

Source Link: Nature Biotechnology

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases

Scientific Reports volume 7, Article number: 1080 (2017)

Source Link: Nature Biotechnology
< Back